Merck advances along a broad PhIII front, aimed at carving up Pfizer’s top-selling vaccine franchise. Could an ambush lay in wait?
Merck has come out of its corner with a 1-2 late-stage punch aimed at one of Pfizer’s biggest franchises. And they’re rolling the late-stage data out around the world to regulators.
Looking to prove that it’s more than just a Keytruda company in R&D, Merck today laid out upbeat top-line results for 2 Phase III studies of V114, their 15-valent rival to Prevnar 13, which has begun to stagnate a little with its $5.8 billion market. That is still Pfizer’s top-selling drug, with a troubled Ibrance coming up in second place.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.